内容概要：量子精密测量借助量子态高敏感性突破经典测量极限，涵盖时频基准、电磁场测量、重力测 量等多个方向，已逐步从实验室走向通信、导航、能源、医疗等实际应用领域，展现出"超精密、高稳 定、抗干扰"的核心优势。中国科学院自主研发的高精度原子钟已达国际先进水准，量子测量产品精度 惊人。中国量子精密测量行业在技术创新和政策支持下蓬勃发展，市场应用呈现迅速扩张的趋势。我国 量子精密测量主要应用于军事国、民用领域（能源、医疗、通信）、科学等领域。2024年我国量子精密 测量市场规模增长至2.95亿美元，在军事国防领域量子精密测量技术市场占据58.98%的市场份额，其次 为民用与科学领域合计约占10.51%。2025年我国量子精密测量市场规模约为4.35亿美元，预计2026年有 望达到5.2亿美元，2035年有望达到10.53亿美元。 上市企业：国盾量子(688027.SH)、天奥电子(002935.SZ)、中国船舶(600150.SH)、西部超导 (688122.SH)、光韵达(300227.SZ)、国睿科技(600562.SH)、天奥电子[002935] 关键词：量子精密测量行业政策、量子精密测量产业链、量子精密测量 ...

Core Viewpoint - Guoyi Quantum has successfully broken the foreign monopoly in high-end scientific instruments and is planning an IPO on the Sci-Tech Innovation Board to support the localization of high-end scientific instruments in China [1]. Group 1: Company Overview - Guoyi Quantum, established in December 2016, is recognized as a national-level specialized and innovative "little giant" enterprise and was included in the list of Chinese unicorn companies in 2024 [5]. - The company focuses on the research and development of high-end scientific instruments, providing essential equipment for quantum technology, materials science, chemical engineering, biomedicine, and advanced manufacturing [10]. - Guoyi Quantum has developed products that have broken the long-standing monopoly of international giants in certain segments of the domestic instrument market, achieving performance metrics that meet or exceed international competitors [10]. Group 2: Leadership and Control - The actual controllers of Guoyi Quantum are He Yu and Rong Xing, who collectively control 34.87% of the voting rights through various indirect holdings [3]. - He Yu, a notable figure from the University of Science and Technology of China (USTC), has held multiple leadership roles and has been recognized with various awards for his contributions to the industry [4]. - Rong Xing, also a USTC alumnus, has a distinguished academic background and has served in various significant positions within the scientific community [4]. Group 3: Financial Performance - Guoyi Quantum's revenue has shown significant growth, with figures of 151.45 million, 400 million, 501 million, and 171 million yuan for the years 2022 to 2025, reflecting year-on-year growth rates of 163.78% and 25.49% for 2023 and 2024 respectively [13]. - Despite the revenue growth, the company has not yet achieved profitability, with net losses reported at -168 million, -169 million, -104 million, and -74 million yuan for the same period [14]. - The company anticipates turning a profit in 2026, contingent on factors such as product strength, market expansion, and cost control [15]. Group 4: Market Position and Competition - The scientific instrument market has been dominated by international firms like Thermo Fisher, Danaher, and Agilent, which have established a strong presence over decades [16]. - Domestic manufacturers, including Guoyi Quantum, are gradually gaining recognition and breaking the monopoly of these international giants through technological advancements [16]. - Guoyi Quantum faces challenges in enhancing brand recognition and overcoming market penetration barriers due to the long-standing dominance of foreign brands [16][17].

Core Viewpoint - The article highlights the growing interest and investment in quantum technology, particularly in the context of China's "14th Five-Year Plan," which includes quantum technology as a strategic growth point for the new economy. The IPO wave in the quantum technology sector is beginning, with Guoyi Quantum Technology (Hefei) Co., Ltd. filing for an IPO on the Sci-Tech Innovation Board [1]. Company Overview - Guoyi Quantum focuses on the research and development of high-end scientific instruments, providing advanced scientific equipment and solutions for various fields, including quantum technology, materials science, and biomedicine [1][4]. - The company has launched several products, including electron paramagnetic resonance spectrometers and scanning electron microscopes, breaking the long-standing dominance of international giants in certain segments of the domestic market [4]. Revenue Composition - From 2022 to the first half of 2025, the revenue share from quantum information technology and spin resonance decreased from 49.32% to 25.26%, while the revenue share from electron microscope series increased from 24.46% to 56.02% [5][6]. - The company’s revenue figures for the years 2022 to 2025 (first half) are approximately 151 million, 400 million, 501 million, and 171 million respectively, with corresponding net losses of approximately -129 million, -146 million, -86 million, and -76 million [11]. Market Dynamics - The global market for laboratory analytical instruments is projected to grow from $82.95 billion in 2024 to $101.58 billion by 2029, with an average annual growth rate of 4.1% [12]. - China's laboratory analytical instrument market is expected to reach $9.28 billion in 2024, with a compound annual growth rate of 4.7% from 2024 to 2029, positioning it as the second-largest market among major economies [14]. Competitive Landscape - The high-end scientific instrument market in China has been dominated by foreign manufacturers, with over 75% of large scientific instruments in universities and research institutions being imported [18]. - Guoyi Quantum faces challenges in terms of historical accumulation, operational scale, product matrix, financial strength, market share, and brand recognition compared to established players like Thermo Fisher and Agilent [18]. Management and IPO Details - Guoyi Quantum, established in 2016, is led by a young management team, including a 1992-born chairman and general manager, He Yu, who has a PhD from the University of Science and Technology of China [21]. - The company aims to raise approximately 1.169 billion for projects related to high-end scientific instrument industrialization, quantum technology research, and application center network construction [22].

Core Insights - The article discusses the recent procurement intentions announced by the Institute of High Energy Physics, Chinese Academy of Sciences, which includes 17 items of scientific instruments with a total budget of 101 million yuan [1][2]. Procurement Overview - The procurement involves high-precision specialized laser tracking instruments, stripe cameras, high-resolution precision control white X-ray detectors, and focused ion beam electron beam dual beam microscopes, with an expected procurement timeline from October to December 2025 [2][3]. Detailed Procurement List - The procurement list includes: - Laser confocal microscope with a budget of 30.52 million yuan, aimed at high-resolution imaging of biological tissues and cells [4]. - Flow cytometer with a budget of 14 million yuan, designed for high-throughput detection and analysis of biological effects [5]. - BII positron source replacement device with a budget of 17.5 million yuan, crucial for the operation of the BII linear accelerator [5]. - LYSO:Ce crystal for energy measurement with a budget of 528 million yuan, intended for the development of calorimeter prototypes [5]. - High-precision chip mounting machine with a budget of 15 million yuan, customized for specific chip mounting requirements [5]. - Stripe camera for electron beam measurement with a budget of 25 million yuan, requiring high-speed scanning capabilities [5]. - High-resolution precision control white X-ray detector with a budget of 14 million yuan, for beam profile measurement [5]. - Voltage regulation device for CSNS-II with a budget of 30 million yuan, to ensure stable operation of low-temperature equipment [5]. - Dedicated ventilation system for CSNS-II laboratories with a budget of 14 million yuan, to maintain environmental standards [5]. - Muon source terminal detector electronics with a budget of 29 million yuan, essential for muon spin spectroscopy [6]. - Two-photon three-dimensional laser direct writing machine with a budget of 12.5 million yuan, for high-precision laser writing [6]. - High-precision three-coordinate measuring system with a budget of 16 million yuan, for precise measurement and calibration [6]. - Multi-functional detection platform with a budget of 38.5 million yuan, for optical component surface shape detection [6]. - Focused ion beam electron beam dual beam microscope with a budget of 45 million yuan, for high-precision micro-machining [6]. - Back-illuminated high-speed CMOS detector with a budget of 32 million yuan, for high frame rate imaging [6].

Core Viewpoint - Guoyi Quantum Technology (Hefei) Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise 1.169 billion yuan, focusing on high-end scientific instrument development for various fields including quantum technology and advanced manufacturing [1][2]. Company Overview - Since its establishment, Guoyi Quantum has focused on the R&D of high-end scientific instruments, providing essential equipment and solutions for global universities, research institutions, and enterprises [1]. - The company has developed products such as electron paramagnetic resonance spectrometers and scanning NV probe microscopes, achieving performance metrics that meet or exceed international competitors, thereby challenging the long-standing dominance of international giants in the domestic high-end scientific instrument market [2]. Market Context - The global scientific instrument market is highly concentrated, with European and American companies dominating due to their technological advantages and brand recognition, particularly in high-precision and complex high-end instruments [1]. - Despite the growing domestic demand for high-end scientific instruments driven by rapid advancements in industries like biomedicine and semiconductors, the domestic production rate remains low, indicating a high dependency on imports [1]. Financial Overview - The company reported revenues of approximately 151 million yuan, 400 million yuan, 501 million yuan, and 171 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively [3]. - The net profit attributable to the parent company for the same periods was -123 million yuan, -140 million yuan, -74.08 million yuan, and -72.58 million yuan, indicating ongoing financial challenges [3]. Investment Projects - The funds raised from the IPO will be allocated to several key projects, including: - High-end scientific instrument industrialization project with a total investment of 784.83 million yuan, of which 454.72 million yuan will be funded by the IPO proceeds - Quantum technology development research institute construction project with a total investment of 449.40 million yuan, fully funded by the IPO proceeds - Application center network construction project with a total investment of 264.83 million yuan, fully funded by the IPO proceeds [3]. Financial Metrics - As of June 30, 2025, the total assets are projected to be approximately 1.307 billion yuan, with equity attributable to the parent company at around 674.66 million yuan [4]. - The company has shown a trend of increasing asset-liability ratios, rising from 19.50% in 2022 to 43.75% in 2025 [4]. - R&D expenditure as a percentage of revenue was 29.78% in 2025, indicating a strong commitment to innovation despite financial losses [4].